Article Figures & Data
Figures
- Figure 1.
Kaplan–Meier curves for (A) progression-free survival and (B) overall survival after enfortumab vedotin monotherapy initiation in patients with advanced urothelial carcinoma stratified by the type of prior immune checkpoint inhibitors.
- Figure 2.
Kaplan–Meier curves for overall survival after enfortumab vedotin monotherapy initiation in patients with advanced urothelial carcinoma stratified by the Bellmunt risk score.
- Figure 3.
Kaplan–Meier curve for overall survival after first-line platinum-based chemotherapy initiation in patients treated with enfortumab vedotin as a late-line treatment stratified by the type of prior immune checkpoint inhibitors.
- Figure 4.
Treatment-related adverse events of enfortumab vedotin stratified by the type of prior immune checkpoint inhibitors.
Tables
In this issue
Jump to section
Related Articles
Cited By...
- Real-world Outcomes of Enfortumab Vedotin in Elderly Patients With Metastatic Urothelial Carcinoma
- Outcomes of Enfortumab Vedotin Treatment in Patients Ineligible for the EV-301 Trial
- Survival and Safety Outcomes of Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma from a Single-Center Experience
- Cancer-induced Pain Is Associated With Poor Overall Survival of Urothelial Carcinoma Patients Treated With Enfortumab Vedotin
- Outcomes of Avelumab Treatment in Advanced Urothelial Carcinoma According to Age, Performance Status, and Timing